Article Text

PDF
SAT0154 Effectiveness and safety of CT-P13 in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis: observational study in republic of korea
  1. D-W Kim1,
  2. T-H Kim2,
  3. SR Kwon3,
  4. EY Lee4,
  5. C-N Son5,
  6. YS Kim6,
  7. SH Kim7,
  8. Y-B Park8,
  9. J-W Hur9,
  10. H-S Lee10,
  11. SJ Lee11,
  12. SH Lee11
  1. 1Inje University Busan Paik Hospital, Busan
  2. 2Hanyang University Hospital for Rheumatic Diseases, Seoul
  3. 3Inha University Hospital, Incheon
  4. 4Seoul National University College of Medicine, Seoul
  5. 5Keimyung University Dongsan Medical Center, Daegu
  6. 6Chosun University Hospital, Gwangju
  7. 7Gwangmyeong Saeum Hospital, Gyeonggi-do
  8. 8Yonsei University Severance Hospital
  9. 9Eulji University Seoul Hospital, Seoul
  10. 10Hanyang University Guri Hospital, Gyeonggi-do
  11. 11Celltrion, Inc., Incheon, Korea, Republic Of

Abstract

Background CT-P13 is approved as a biosimilar of innovator infliximab for marketing in 79 countries around the world. After approval, observational study has been conducted in Republic of Korea in patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) and Plaque Psoriasis (PS).

Objectives To evaluate the effectiveness and safety of CT-P13 under routine care in Republic of Korea.

Methods This observational study included both biologic naïve patients (Naïve group) and patients who switched from other anti-tumor necrosis factor (TNF)s to CT-P13 (Switch group). Effectiveness were evaluated based on remission (DAS28≤2.6 in RA, BASDAI<3 in AS and absence of swollen and tender joint counts in PsA), and response (BASDAI 20/50/70 in AS and PASI 50/75 in PS). Adverse events (AEs) were collected over 6 month period.

Results Total 940 patients (400 with RA, 531 with AS, 3 with PsA and 6 with PS) were registered and 338 (36.0%) patients (108 with RA, 228 with AS, 2 with PS) who switched to CT-P13 were included.

The proportion of patients achieving remission was similar between Naïve and Switch groups in both RA and AS during post-baseline visits (Table 1). In RA, the proportion of patients achieving each disease activity category by DAS28 was similar between Naïve and Switch groups (Figure 1). The proportion of patients who achieved BASDAI 20/50/70 response gradually increased from week 6 to week 24 or 30 in Naïve group with AS (Figure 1).

Fifty percent of naïve patients with PsA achieved clinical remission. The proportions of both PASI 50 and 75 responses were 50% at Week 22 in Naïve group and were 100% and 50% in Switch group, respectively during post-baseline visits in PS patients.

Throughout this study, treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events (TESAE) were reported as Table 2. Only 11% of patients experienced infection.

Table 1.

Clinical remission in RA and AS

Table 2.

Summary of safety results

Conclusions CT-P13 is efficacious and well-tolerated in RA/AS/PsA/PS patients. Efficacy and safety results in patients treated with CT-P13 were clinically consistent to historical data [1,2,3]. Especially, Switch group results showed that CT-P13 provides a useful alternative to other anti-TNFs.

References

  1. Kobayashi et al (2016).

  2. Hetland et al (2005).

  3. Hetland et al (2010).

References

Disclosure of Interest D.-W. Kim: None declared, T.-H. Kim: None declared, S. R. Kwon: None declared, E. Y. Lee: None declared, C.-N. Son: None declared, Y. S. Kim: None declared, S. H. Kim: None declared, Y.-B. Park: None declared, J.-W. Hur: None declared, H.-S. Lee: None declared, S. J. Lee Employee of: CELLTRION,Inc., S. H. Lee Employee of: CELLTRION,Inc.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.